Amoy Diagnostics Future Growth

Future criteria checks 5/6

Amoy Diagnostics is forecast to grow earnings and revenue by 21.6% and 20.2% per annum respectively. EPS is expected to grow by 21.5% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

21.6%

Earnings growth rate

21.5%

EPS growth rate

Biotechs earnings growth	38.8%
Revenue growth rate	20.2%
Future return on equity	17.7%
Analyst coverage	Good
Last updated	19 Aug 2024

Recent future growth updates

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Recent updates

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01

Earnings and Revenue Growth Forecasts

SZSE:300685 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,872	476	346	399	8
12/31/2025	1,555	387	295	314	9
12/31/2024	1,279	313	225	261	9
6/30/2024	1,128	279	262	295	N/A
3/31/2024	1,082	268	274	312	N/A
12/31/2023	1,044	261	254	299	N/A
9/30/2023	951	213	222	269	N/A
6/30/2023	908	301	164	222	N/A
3/31/2023	831	267	108	189	N/A
1/1/2023	842	264	71	149	N/A
9/30/2022	871	287	75	140	N/A
6/30/2022	911	218	81	146	N/A
3/31/2022	949	250	88	134	N/A
1/1/2022	917	240	94	168	N/A
9/30/2021	890	231	107	196	N/A
6/30/2021	844	211	125	224	N/A
3/31/2021	811	198	143	235	N/A
12/31/2020	728	180	163	221	N/A
9/30/2020	650	153	114	167	N/A
6/30/2020	595	138	126	159	N/A
3/31/2020	550	129	143	170	N/A
12/31/2019	578	135	128	152	N/A
9/30/2019	541	140	126	153	N/A
6/30/2019	502	135	87	120	N/A
3/31/2019	469	134	66	104	N/A
12/31/2018	439	127	54	93	N/A
9/30/2018	398	122	71	108	N/A
6/30/2018	384	120	88	114	N/A
3/31/2018	357	103	N/A	96	N/A
12/31/2017	330	94	N/A	92	N/A
9/30/2017	315	82	N/A	70	N/A
6/30/2017	288	78	N/A	49	N/A
3/31/2017	258	67	N/A	40	N/A
12/31/2016	253	67	N/A	32	N/A
6/30/2016	220	42	N/A	24	N/A
3/31/2016	198	32	N/A	22	N/A
12/31/2015	177	21	N/A	19	N/A
12/31/2014	107	19	N/A	16	N/A
12/31/2013	74	22	N/A	9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300685's forecast earnings growth (21.6% per year) is above the savings rate (2.9%).

Earnings vs Market: 300685's earnings (21.6% per year) are forecast to grow faster than the CN market (17% per year).

High Growth Earnings: 300685's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300685's revenue (20.2% per year) is forecast to grow faster than the CN market (10.5% per year).

High Growth Revenue: 300685's revenue (20.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300685's Return on Equity is forecast to be low in 3 years time (17.7%).

Amoy Diagnostics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Price target decreased by 7.6% to CN¥29.52

Price target decreased to CN¥35.47

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Price target decreased to CN¥82.96

Recent updates

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Full year 2023 earnings: EPS exceeds analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Price target decreased by 7.6% to CN¥29.52

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥35.47

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

Price target decreased to CN¥82.96

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Price target decreased to CN¥93.33

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Price target increased to CN¥105

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26

New 90-day high - CN¥79.53

Amoy Diagnostics Co., Ltd. to Report First Half, 2020 Results on Jul 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies